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Impact of Race on Outcomes of Patients with Non-small
Cell Lung Cancer
Ayesha S. Bryant, MSPH, MD,* and Robert James Cerfolio, MD, FACS, FCCP†
Objective: Examination of factors that may contribute to racial
disparity among those with lung cancer has been thwarted by
heterogeneous treatment and staging strategies, limited national
registry and socioeconomic and follow-up data. This study examines
a decades worth of data to better elucidate these factors in a cohort
staged or treated using homogeneous algorithms.
Methods: A nested case-control study of patients with non-small
cell lung cancer (NSCLC). White patients were matched 4:1 to
African American patients on age, gender, comorbidities, perfor-
mance status, and stage. All patients underwent clinical and patho-
logic staging by one physician using similar staged-based treatment
algorithms. Socioeconomic status was assessed by annual income
per capita, insurance status, and education level. The primary out-
come was survival rate.
Results: Among the 930 patients in this series, African Americans
were more likely to be smokers (p 0.001), have a lower per-capita
annual income (p  0.016), greater delay to treatment (p  0.023),
and less likely to agree to neo-adjuvant therapy (p  0.001). Whites
had better 5-year overall survival than African Americans for stage
I (84% versus 78%, p  0.037), stage II (52% versus 44%, p 
0.041), and stage III (32% versus 20%, p  0.008) NSCLC.
However, this survival advantage disappeared for earlier stages of
NSCLC (I and II) when adjusted for socioeconomic status and
smoking status. The survival advantage for stage IIIa was lost when
adjusted for neo-adjuvant chemoradiotherapy. African American
men had the worst survival of all subgroups independent of socio-
economic status.
Conclusions: Given uniform staging, treatment, and socioeconomic
status the overall survival rates for African American and White
patients with NSLC are similar.
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Although smoking rates have declined in the United States,lung cancer continues to be a pandemic.1 It is the number
one cause of cancer related deaths world-wide. In 2006 there
were an estimated 174,000 patients diagnosed with lung
cancer and 162,000 deaths due to lung cancer in the United
States alone.1 Bronchogenic malignancy has been shown in
large registry databases to have racial disparity in clinico-
pathologic characteristics and in survival. However, these
databases feature inconsistent staging, many different treating
physicians, and multiple treatment strategies and a whole host
of other confounders.
Advances in genetics and the social sciences have dem-
onstrated that race, in and of itself, is usually not a relevant
biologic factor; rather it is a complex variable heavily impacted
by strong socioeconomic associations.2 Mortality from lung
cancer still remains highest in the African American popula-
tion.3–5 Given the striking differences in survival between
patients with early stage lung cancer who undergo surgical
resection and those who have alternative treatments, it is not
surprising that research has shown that some of the higher
mortality in African Americans with early stage non-small
cell lung cancer (NSCLC) may be attributed to differences in
surgical rates.4 These rates are affected by stage, lead time
bias, access to healthcare, and patient’s and physician’s
attitude towards surgery, chemotherapy and radiation. There-
fore, we attempted to minimize these effects. The goal of this
study was to assess the survival difference between African
American and White patients with NSCLC who received
comparable staging tests and procedures and similar treat-
ment. In addition, we attempted to control for the effect that
socioeconomic status and access to health care might play.
METHODS
Study Design and Definitions
This study evaluates a consecutive cohort of patients
with biopsy proven NSCLC, all pathologically staged using a
similar algorithm by one physician. Patients were enrolled
and followed from January 1997 to January 2007. Patients
were excluded if they were 19 years of age or younger, had
histology that was not NSCLC, or if they received neo-
adjuvant chemoradiotherapy without biopsy proven N2 dis-
ease. The University of Alabama at Birmingham’s institu-
tional review board approved this study and the prospective
database used to collect the data. Patient consent was ob-
tained for entry into the prospective database. This consent
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advised patients that the information in the prospective data-
base may be used for future research.
The socioeconomic status of each patient was deter-
mined by using patients per capita annual income (self-
reported), health insurance status (verified), and highest ed-
ucational achievement (self-reported). Median per capita
income was calculated by taking the patients average annual
household income divided by the number of persons residing
in the household. Health insurance status was stratified into
four categories: patients with Medicare with a private sec-
ondary insurance company, any Health Maintenance Organi-
zation, or those covered by any private company were labeled
as “privately insured”, patients with Medicare only were
labeled as “Medicare insured”, patients with Medicaid only
were labeled as Medicaid insured, and those with no insur-
ance were classified as “uninsured.” Highest educational
achievement was self-reported and separated into the follow-
ing categories: some high school but did not graduate, grad-
uated high school or received General Educational Develop-
ment, 2-year college (some college or associates degree),
graduated 4-year college, masters or equivalent graduate
level degree, and doctorate level degree. Time interval until
patient presented to specialist was counted as the number of
days between first abnormal chest radiograph to the date the
patient initially presented to a pulmonologist, oncologist or
thoracic surgeon.
Preoperative Staging
All patients were clinically staged using 5 mm colli-
mated computed tomography (CT scan) of the chest and
upper abdomen and in addition all patients underwent dedi-
cated positron emission tomography (PET) using 2-dexoy-2-
18F –flouro-D-glucose F-18 (FDG-PET or PET/CT) scan.
Pathologic staging was required for inclusion into this study.
All suspicious mediastinal nodes (N2 and/or N3) with a
maximum SUV (maxSUV) 2.5 on FDG-PET scan or 1
cm in greatest axis on CT scan were biopsied before pulmo-
nary resection. Mediastinoscopy and/or endoscopic ultra-
sound fine needle aspirate were used to biopsy different nodal
stations as previously described.6 All suspicious metastatic
(M1) sites by FDG-PET or by CT scan were also investigated
and/or biopsied. Patients with suspected M1 disease in the
liver, adrenal, or contralateral lung underwent definitive bi-
opsy to prove or disprove M1 cancer. If the bone or brain was
suspected to harbor metastases, magnetic resonance imaging
was considered the standard reference. The tumor, node,
metastasis pathologic stage was assigned using the interna-
tional staging system.7
Treatment Strategy
In general, patients with stage I and II disease under-
went resection through thoracotomy with complete thoracic
lymphadenectomy. Those with biopsy-proven stage IIIa dis-
ease because of metastasis lymph node involvement proving
N2 disease underwent platinum based chemotherapy with
concurrent radiotherapy (chemo-radiotherapy). Selected pa-
tients with stage IV disease who underwent complete resec-
tion (some with a single brain metastasis and others with
unsuspected M1 nodules in the same lung) were included in
this study and were labeled as stage IV disease but were
completely resected.
Patients who had biopsy proven N2 disease underwent
platinum based chemoradiotherapy (using 4500–6600 cGy)
and were restaged with a chest CT and dedicated PET or
PET/CT scans. If they were N2 negative after the completion
of their neo-adjuvant therapy, they underwent resection. If a
patient had biopsy proven N3 or M1 disease they were treated
with additional chemoradiotherapy and not resected. Patients
who were N2 negative underwent thoracotomy with complete
resection. At thoracotomy, a complete thoracic lymphadenec-
tomy (not nodal sampling) was used exclusively. Pathologic
review was performed by means of standard techniques,
immuno-histochemical staining, and marker testing were em-
ployed when appropriate.
Statistical Analysis
Continuous data are presented as medians and categor-
ical data are presented as percentages. Characteristics of the
patients and treatments were compared by Fisher exact test or
Pearson’s 2 test for categorical data and by the Wilcoxon
test for continuous data. Survival estimates were derived by
Kaplan-Meier analysis and log-rank test were used to assess
differences in survival among the groups. Stratified log-rank
analyses and Cox proportional-hazards modeling were used
to investigate and adjust for major prognostic and stratifica-
tion factors. Variables with p values 0.10 in univariate
analysis were included in the step wise multivariate model. A
two-sided p value of 0.05 was considered statistically
significant. Patients alive at the end of the study period were
censored for purposes of data analysis. Analysis was per-
formed using the SAS software v. 9.0.
Data Collection and Follow-up
Patients were actively followed after pathologic staging
and treatment to the end of this study. For patients who were
completely resected, follow-up consisted of chest and abdom-
inal CT scan every 6 months for the first 2 years and yearly
afterward. Patients who were not completely resected under-
went more frequent follow-up with their onocologist and/or
surgical oncologist. Outcomes and follow-up data was ob-
tained from multiple sources such as: clinic letters, follow-up
scans, hospital computer information systems, tumor registry,
social security death index, telephone calls, and letters from
oncologists and other physicians. The time to disease recur-
rence (defined as biopsy-proven NSCLC), progression or
death due to lung cancer was recorded. All information was
entered into our prospective database. Data acquisition for
new patients was stopped on January 2007 for this study but
patient follow-up continued until March 2007.
RESULTS
Patient Characteristics
Between January 1997 and January 2007, 1813 patients
eligible for this study presented with NSCLC. Of those
patients, 186 were African American and 1,627 were Whites.
Each African American patient was matched with four White
patients (744) on gender, age (within 5 years), health
Bryant and Cerfolio Journal of Thoracic Oncology • Volume 3, Number 7, July 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer712
performance status, and treatment. Patient demographics,
preoperative, and socioeconomic characteristics are shown in
Table 1. Smoking history, per capita annual income, time to
presentation, and health insurance type differed significantly
between the two groups (p  0.001, p  0.016, p  0.023
and p 0.008 respectively). Table 2 shows the operative and
pathologic characteristics of African Americans and Whites.
There was no significant difference in the histology and stage
between the two groups.
Figure 1 shows the proportion of patients who received
neo-adjuvant therapy for preoperative mediastinal (N2) dis-
ease and their survival rates. Seventeen percent of African
Americans declined neo-adjuvant therapy as compared with
only 2% of Whites; this difference was statistically signifi-
cantly different (p  0.001). Among the patients that did
receive neo-adjuvant therapy, the 5-year and 7-year survivals
were similar for African Americans and Whites (p  0.10).
Survival Analysis
Kaplan-Meier analysis showed socioeconomic status
(annual per capita income, insurance status, and education
level) and time until presentation for treatment to be predic-
tors of survival. Figure 2 shows that Whites had a greater
overall 7-year survival than African Americans, however, this
difference was not statistically significant (23% for Whites
compare with 18% for African Americans, p  0.15). Cox
Hazards regression analysis showed that annual per capita
income (p  0.031) and time until presentation (p  0.002)
were independent predictors of survival.
Stage specific Kaplan-Meier survival analysis showed
that White patients had a significantly greater 5-year survival
than African American patients for stages I, II and III
NSCLC. Smoking rate significantly impacted all three stages,
however, per capita income and time until presentation for
treatment impacted survival in patients with early stage
NSCLC only (stages I and II). Because the majority of
patients with stage III disease were stage IIIA from N2
disease, we further analyzed the stage IIIa patients who
had N2 disease by controlling for neo-adjuvant chemo-
radiotherapy and found no statistically significant differ-
ence in the 7-year survival rates between African Ameri-
cans and Whites.
Gender specific Kaplan-Meier analysis showed no sig-
nificant difference in survival rates of African American
women and White women (p  0.181). Among men how-
ever, White men had a higher 7-year survival rate compared
with African American men (31% compared with 18%, p 
0.008). Smoking rate and time until presentation for treatment
were the only independent predictors on Cox Hazards anal-
ysis (p  0.007) for African American men. Median fol-
low-up period was 4.8 years (range, 2 months–10.1 year).
Seventy-three (8%) patients were lost to follow-up.
DISCUSSION
Lung cancer is the number one cause of cancer
deaths world-wide and there may be genetic, biologic,
and/or epidemiologic factors that lead to different survival
rates in subgroups of patients. For example, women are
more likely to develop adenocarcinoma and have a better
5-year survival than men.8 –12 This is true even when
patients are carefully pathologically staged and completely
TABLE 1. Patient Demographics, Preoperative and
Socioeconomic Characteristics
White
n  744
African
American
n  186 p
Gender
Male 308 (41%) 77 (41%) Matched
Female 436 (59%) 109 (59%)
Age (median in yr, range) 61 (22–89) 59 (24–85) Matched
Pulmonary Function (median)
FEV1%* 80% 81% 0.822
DLCO%* 69% 72%
MVV%* 77% 79%
History of smoking 536 (72%) 158 (85%) 0.001
Median ECOG score (range, 0–5) 0 0 Matched
History of cardiovascular disease† 275 (37%) 72 (42%) 0.633
Insurance status
Private 364 (49%) 65 (35%) 0.001
Medicare only 290 (39%) 73 (39%)
Medicaid only 45 (6%) 21 (11%)
Uninsured 45 (6%) 27 (15%)
Annual income (per capita) $10,500 $8,250 0.016
Highest education level (median) 2 yr college HS grad/GED 0.459
Time until presentation for
treatment (median wk)
2.8 4.3 0.023
Neo-adjuvant therapy 224 (30%) 48 (26%) 0.361
Adjuvant chemotherapy‡ 59 (10%) 14 (9%) 0.421
*All values are median values and are percent predicted for: Forced Expiratory
Volume (FEV1), Maximum Voluntary Ventilation (MVV), and Diffusion Limited
Carbon Monoxide (DLCO).
†Defined as history of coronary artery bypass grafting, left ventricular function
35%, hypertension, myocardial infarction, angina, or coronary artery stent.
‡Denominator includes only patients that underwent a complete resection.
TABLE 2. Operative and Tumor Characteristics
White African American p
Treatment
Not-resected: Mediastinoscopy,
EUS-FNA, VATS and/or
wedge
149 (20%) 37 (20%) Matched
Resected 595 (80%) 149 (80%)
Histology
Adenocarcinoma 298 (40%) 67 (36%) 0.780
Squamous cell carcinoma 365 (49%) 96 (51%)
Other* 81 (11%) 23 (12%)
Pathologic stage of NSCLC (after mediastinoscopy, EUS-FNA, etc, prior
to any neo-adjuvant therapy)
0 15 (2%) 4 (2%) 0.713
I 424 (57%) 95 (51%)
II 97 (13%) 30 (16%)
III 193 (26%) 53 (29%)
IV 15 (2%) 4 (2%)
*Other category includes unspecified NSCLC, mixed cancer types such as adeno-
squamous carcinoma, large cell, carcinoid, bronchoalveolar carcinoma.
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resected.13 Likewise, previous reports have suggested that
race also plays an important factor in the survival of
patients with NSCLC.
Possible genetic factors have been presented to explain
the poor survival of African Americans patients compared
with White patients. Perez-Stable in 1998 reported a higher
prevalence of genetic polymorphisms in African Americans
compared with Whites.14 They observed that African Amer-
ican smokers had a higher serum level of cotinine despite
similar daily cigarette consumption and a 30% higher intake
of nicotine per cigarette than Whites. Smoking patterns that
vary by race may also account for some of these reported
survival discrepancies. Although African American smokers
seem to begin smoking at a later age, they are less likely to
quit once started. In 1987, the quit rate for African Amer-
ican smokers was 32% as compared with 47% for White
smokers.15 Additionally, Cummings in 1987 reported an
increased use of mentholated cigarettes in African Amer-
icans (70 – 80%) as compared with Whites (20–30%).16
Mentholated cigarettes have a higher tar content,17 higher
levels of carcinogens,18 facilitate the absorption of carbon
monoxide and decrease ventilation leading to greater pulmo-
nary retention of tobacco smoke. Hence because of these
reports and our practice that employs consistent, careful
clinical, and pathologic staging of all patients and life-time
follow-up, we decided to prospectively evaluate the impact of
epidemiological and socioeconomic variables on survival
rates for our patients with NSCLC.19
In this study we found no significant difference in the
survival of White patients compared with African American
patients once we controlled for socioeconomic status vari-
ables and time until presentation for treatment. Smoking rates
impacted survival only in men. Additionally, African Amer-
icans were more likely to refuse preoperative chemo-radio-
therapy compared with Whites. Thus our data suggests that
the difference in survival between White and African Amer-
icans is not genetic or biologic but rather may be related to
access to health care and/or the patient’s perception of health-
care and of various treatments.
In our report, African Americans were less likely to
agree to neo-adjuvant chemo-radiotherapy for N2 disease,
despite the recommendations for both groups to be the same.
Earle in 2000 reported that there was wide variation in the
utilization of palliative chemotherapy among Medicare pa-
tients, and nonmedical factors were strong predictors of
whether a patient received chemotherapy or not.20 Other
factors that may influence type of treatment are patient
perception, racial and cultural differences, expense, logistical
issues, and performance status. Thus when we when con-
trolled for socioeconomic status variables the survival gap
between African Americans and Whites narrowed consider-
ably. Although this type of study cannot be performed using
the Surveillance, Epidemiological, End-Results database (be-
cause of inconsistent staging and treatment strategies and lack
of smoking history data), previous reports using Surveillance,
Epidemiological, End-Results have shown that most African
American cancer patients live in high density areas with
lower median income.
FIGURE 1. Incidence and survival rates for
patients with mediastinal (N2) nodal involve-
ment, diagnosed preoperatively who received
neo-adjuvant chemo-radiotherapy by race.
FIGURE 2. Actuarial survival for all patients (n  930) ad-
justed for smoking rates, income, time until presentation
and education level. The overall 7-year survival was higher in
Whites compared with African Americans, although this dif-
ference was not statistically significant (p  0.149).
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The strengths of our study include that all patients were
treated by one physician, patients come from similar geo-
graphic regions, received a dedicated PET or PET/CT before
surgery, availability of socioeconomic data (income, educa-
tional level) and those who underwent surgery received a
complete thoracic lymphadenectomy. Additionally, we were
able to assess temporal differences in presentation for treat-
ment between the groups. In a Veterans Administration study
evaluating outcomes of patients with NSCLC or colon can-
cer, the survival of African Americans was equivalent to
Whites, suggesting that equal access to comparable health
care results in equal outcomes.21 All of these facts limit
confounding and stage migration. We also sought to elimi-
nate known confounders of survival by matching on some of
these characteristics. For example, we matched on perfor-
mance status, comorbidities, and age. Age has been found to
be a predictor for treatment choices—–elderly patients have
been found to be less accepting of potentially curative surgi-
cal treatments for difference cancers including early stage
NSCLC.19,22 Limitations of this study include that it is uni-
institutional. Additionally, measurements of factors such as
personal beliefs, surgical acceptance, racial and cultural dif-
ferences cannot be objectively measured.
In conclusion, we found that White patients had better
survival than African American patients overall and for stage
I, II and III NSCLC on univariate analysis. However, when
we adjusted for socioeconomic status and time to access to
care, the racial disparity faded and the advantage was lost for
those with early stage lung cancer (stages I or II). When we
adjusted for neo-adjuvant therapy rates for stage IIIA disease,
the survival advantage for stage III disease also disappeared.
Smoking only impacted survival in African American men.
These data suggest the difference in survival between African
American and White patients may not be genetic or biologic,
but rather socioeconomic. Increased education and more
prompt healthcare access may improve the dismal survival
for patients with non-small cell lung cancer, in particular
African American patients.
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